Tatva Chintan Pharma Chem Ltd
NSE:TATVA
Tatva Chintan Pharma Chem Ltd
Tatva Chintan Pharma Chem Ltd. is a chemicals manufacturing company. The company is headquartered in Vadodara, Gujarat. The company went IPO on 2021-07-29. The firm is engaged in the manufacturing of verity of chemicals include structure directing agents (SDAs), phase transfer catalysts (PTCs), electrolyte salts for capacitor batteries, and pharmaceutical and agrochemical intermediates, and other specialty chemicals (PASC). Its SDAs are quarternary salts, which helps in the formation of channels and pores during the synthesis of zeolites. Its PTCs are used to facilitate the migration of a reactant from one phase into another phase where the reaction occurs in a heterogeneous multi-phase system. The firm operates two manufacturing facilities situated at Ankleshwar and Dahej in Bharuch, Gujarat, India. The firm is focused on serving various customers across various industries, including the automotive, petroleum, pharmaceutical, agro chemicals, paints and coatings, dyes and pigments, personal care and flavors and fragrances industries.
Tatva Chintan Pharma Chem Ltd. is a chemicals manufacturing company. The company is headquartered in Vadodara, Gujarat. The company went IPO on 2021-07-29. The firm is engaged in the manufacturing of verity of chemicals include structure directing agents (SDAs), phase transfer catalysts (PTCs), electrolyte salts for capacitor batteries, and pharmaceutical and agrochemical intermediates, and other specialty chemicals (PASC). Its SDAs are quarternary salts, which helps in the formation of channels and pores during the synthesis of zeolites. Its PTCs are used to facilitate the migration of a reactant from one phase into another phase where the reaction occurs in a heterogeneous multi-phase system. The firm operates two manufacturing facilities situated at Ankleshwar and Dahej in Bharuch, Gujarat, India. The firm is focused on serving various customers across various industries, including the automotive, petroleum, pharmaceutical, agro chemicals, paints and coatings, dyes and pigments, personal care and flavors and fragrances industries.
Revenue Surge: Tatva Chintan reported Q3 FY26 revenue of INR 1,313 million, up 53% year-on-year and 6% sequentially.
EBITDA Growth: EBITDA rose 261% year-on-year to INR 255 million, with a 15% increase quarter-over-quarter.
Business Segment Trends: Pharma & Agro Intermediates grew sharply (up 45% QoQ, 86% YoY), while Phase Transfer Catalysts and Structured Directing Agents faced modest sequential declines but strong annual growth.
Operational Expansion: The new Dahej plant block is ready, with commercial production expected to start in March; Jolva greenfield CapEx of INR 250–275 crores targeted for completion in 18 months.
Outlook & Guidance: Management forecasts 20–30% annual revenue growth in FY26 and FY27, targeting INR 850–900 crores revenue in 2.5–3 years, with EBITDA margins expected to stabilize at 20–22%.
Sector Recovery: Management sees clearer stability and improved demand in chemicals, especially in new Agro and energy storage products, despite ongoing industry-wide challenges.
Semiconductor Progress: First plant-scale semiconductor chemical trial orders received; management sees long-term, sizable opportunity materializing post-2028.
